×
About 2,230 results

ALLMedicine™ Focal Segmental Glomerulosclerosis Center

Research & Reviews  836 results

Kidney Biopsy Features Most Predictive of Clinical Outcomes in the Spectrum of Minimal ...
https://doi.org/10.1681/ASN.2021101396
Journal of the American Society of Nephrology : JASN; Zee J, Liu Q et. al.

May 18th, 2022 - Heterogeneity in disease course and treatment response among patients with MCD/FSGS necessitates a granular evaluation of kidney tissue features. This study aimed to identify histologic and ultrastructural descriptors of structural changes most pr...

Pathogenesis of Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT00001392

May 13th, 2022 - The present protocol seeks to advance our understanding of sclerosing glomerular and tubulointerstitial kidney diseases, including but not limited to variants of focal segmental glomerulosclerosis (FSGS) and chronic kidney disease of unknown etiol...

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
https://clinicaltrials.gov/ct2/show/NCT05003986

May 11th, 2022 - This is a multicenter, open-label, 108-week study of sparsentan in approximately 57 pediatric subjects aged ≥1 year to <18 years with selected proteinuric glomerular diseases, divided into 2 populations, defined as follows: Population 1: Subjects ...

Efficacy of intravenous combined immunosuppression with plasmapheresis in adult patient...
https://doi.org/10.1002/jca.21985
Journal of Clinical Apheresis; Dirim AB, Demir E et. al.

May 11th, 2022 - Primary focal segmental glomerulosclerosis (FSGS) treatment is based on immunosuppressive therapies. Since refractory disease is common, alternative methods are emerging. One of these methods is plasmapheresis with intravenous cyclosporine and cor...

Susceptibility to kidney fibrosis in mice is associated with early growth response-2 pr...
https://doi.org/10.1016/j.kint.2022.03.029
Kidney International; Kökény G, Németh Á et. al.

May 6th, 2022 - Patients with chronic kidney disease and experimental animal models of kidney fibrosis manifest diverse progression rates. Genetic susceptibility may contribute to this diversity, but the causes remain largely unknown. We have previously described...

see more →

Guidelines  2 results

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Impr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983378
Kidney International; Swanepoel CR, Atta MG et. al.

Feb 6th, 2018 - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulti...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  22 results

Pathogenesis of Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT00001392

May 13th, 2022 - The present protocol seeks to advance our understanding of sclerosing glomerular and tubulointerstitial kidney diseases, including but not limited to variants of focal segmental glomerulosclerosis (FSGS) and chronic kidney disease of unknown etiol...

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
https://clinicaltrials.gov/ct2/show/NCT05003986

May 11th, 2022 - This is a multicenter, open-label, 108-week study of sparsentan in approximately 57 pediatric subjects aged ≥1 year to <18 years with selected proteinuric glomerular diseases, divided into 2 populations, defined as follows: Population 1: Subjects ...

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT05213624

May 3rd, 2022 - This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSG...

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
https://clinicaltrials.gov/ct2/show/NCT03448692

May 2nd, 2022 - The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.

Thrombin Generation Assay to Assess Thrombotic Risk in Nephrotic Patients
https://clinicaltrials.gov/ct2/show/NCT05301829

Mar 31st, 2022 - Thrombin generation test will be performed prospectively in nephrotic patients with various diseases (Minimal Change Disease (MCD), Malignant Nephrosclerosis (MN), Focal Segmental GlomeruloSclerosis (FSGS), diabetic glomerulopathy…) at diagnosis, ...

see more →

News  27 results

Nephrotic Syndrome Patients at High Risk of Kidney Failure, Vascular Problems
https://www.medscape.com/viewarticle/954056

Jul 1st, 2021 - NEW YORK (Reuters Health) - Adults with primary nephrotic syndrome (NS) had close to a 20 times greater risk of developing kidney failure and higher risks of several cardiovascular diseases and death compared to those without NS in a large analysi...

Protein Predicts Risk of AKI in COVID-19 Patients
https://www.medscape.com/viewarticle/939052

Oct 13th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Admission levels of a specific protein predict the development of acute kidney injury (AKI) as well as the need for dialysis in patients hospitali...

Late-onset neutropenia more common than expected in patients on rituximab
https://www.mdedge.com/rheumatology/article/228758/lupus-connective-tissue-diseases/late-onset-neutropenia-more-common
Steve Cimino

Sep 18th, 2020 - A new study has found that late-onset neutropenia is a notably common and occasionally serious occurrence in rituximab-treated patients with autoimmune diseases. Dr.

BRIEF-Vifor Pharma: VFMCRP And Chemocentryx Announce Topline Data From Phase-II Lumina-1 Trial Of CCX140 In Focal Segmental Glomerulosclerosis
https://www.reuters.com/article/brief-vifor-pharma-vfmcrp-and-chemocentr/brief-vifor-pharma-vfmcrp-and-chemocentryx-announce-topline-data-from-phase-ii-lumina-1-trial-of-ccx140-in-focal-segmental-glomerulosclerosis-idUSASN0006W6

May 18th, 2020 - May 18 (Reuters) - VIFOR PHARMA AG: * VFMCRP AND CHEMOCENTRYX ANNOUNCE TOPLINE DATA FROM PHASE-II LUMINA-1 TRIAL OF CCX140 IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Rituximab for Nephrotic Syndrome in Kids: A Note of Caution
https://www.medscape.com/viewarticle/904069

Feb 24th, 2020 - First-line Therapy for Nephrotic Syndrome: A Comparison Idiopathic nephrotic syndrome is the most common disorder of glomerular function in pediatrics.[1] Approximately 40% of children diagnosed with idiopathic nephrotic syndrome will have a relap...

see more →

Patient Education  1 results see all →